Bevacizumab (Avastin®) is an anti-angiogenesis drug used in treatment of cancer.
It is used in combination with standard chemotherapy drugs in patients with metastatic colorectal cancer. The U.S. Food and Drug Administration approved bevacizumab for use in colon cancer 2004. The medicine was developed by Genentech and is marketed, in the United States by Genentech and elsewhere by Roche (Genentech's parent company), under the brand name Avastin.

Avastin.com - Official pharmaceutical website with information for patients and health professionals.
Meta Description: [ Avastin has been approved by the FDA in combination with a specific type of chemotherapy (intravenous 5-fluorouracil [5-FU]-based chemotherapy) for first-line or second-line treatment of people diagnosed with metastatic colorectal cancer. ]
MedlinePlus: Bevacizumab (Systemic) - Data provided by NLM, the National Institutes of Health (NIH), government agencies and health-related organizations. Provides information on usage, precautions, side effects and brand names when available.
Meta Description: [ Bevacizumab(Systemic) ]